Avanir Licenses North American Rights to OptiNose’s NDA-Ready Drug-Device Combination for Migraine
By Heather Cartwright
Pharma Deals Review: Vol 2013 Issue 7 (Table of Contents)
Published: 17 Jul-2013
DOI: 10.3833/pdr.v2013.i7.1966 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Avanir Pharmaceuticals has licensed North American rights to OptiNose’s Breath Powered™ intranasal delivery system containing low-dose sumatriptan powder for the treatment of acute migraine...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS